Gregory P. Geba

7.8k total citations · 1 hit paper
93 papers, 5.9k citations indexed

About

Gregory P. Geba is a scholar working on Physiology, Immunology and Pharmacology. According to data from OpenAlex, Gregory P. Geba has authored 93 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Physiology, 24 papers in Immunology and 22 papers in Pharmacology. Recurrent topics in Gregory P. Geba's work include Asthma and respiratory diseases (42 papers), Inflammatory mediators and NSAID effects (21 papers) and Allergic Rhinitis and Sensitization (12 papers). Gregory P. Geba is often cited by papers focused on Asthma and respiratory diseases (42 papers), Inflammatory mediators and NSAID effects (21 papers) and Allergic Rhinitis and Sensitization (12 papers). Gregory P. Geba collaborates with scholars based in United States, Japan and United Kingdom. Gregory P. Geba's co-authors include Jack A. Elias, Robert Homer, Richard A. Flavell, Yong Zhang, Jingming Wang, Qingsheng Chen, Néstor A. Molfino, John A. Rankin, Ulla-Angela Temann and Robert K. Zeldin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Investigation.

In The Last Decade

Gregory P. Geba

91 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production

1999 1.4k citations Gregory P. Geba et al. profile →

Peers

Countries citing papers authored by Gregory P. Geba

Since Specialization

Citations

This map shows the geographic impact of Gregory P. Geba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory P. Geba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory P. Geba more than expected).

Fields of papers citing papers by Gregory P. Geba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory P. Geba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory P. Geba. The network helps show where Gregory P. Geba may publish in the future.

Co-authorship network of co-authors of Gregory P. Geba

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory P. Geba. A scholar is included among the top collaborators of Gregory P. Geba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory P. Geba. Gregory P. Geba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip 2025 ·BMC Musculoskeletal Disorders ·Stephen J. DiMartino, Haitao Gao, (unknown), Guillermo J. Valenzuela, Thomas Fuerst, Chetachi A. Emeremni, (unknown), Hazem E. Hassan, K. C. Turner, John D. Davis, Souhil Zaim, Jesse T. Chao, (unknown), (unknown), (unknown), (unknown), Michael R. Fetell, (unknown), Gregory P. Geba, Paula Dakin	1
2	Prevalence of preexisting articular bone pathology in patients with osteoarthritis screened for fasinumab clinical trials identified by X-ray or magnetic resonance imaging 2024 ·Osteoarthritis and Cartilage ·Stephen J. DiMartino, Haitao Gao, Tuhina Neogi, Thomas Fuerst, Souhil Zaim, Simon Eng, (unknown), (unknown), (unknown), Gregory P. Geba, Paula Dakin	1
3	Thematic analysis to explore patients’ experiences with long COVID-19: a conceptual model of symptoms and impacts on daily lives 2024 ·BMJ Open ·Diana Rofail, Selin Somersan-Karakaya, (unknown), (unknown), Yuming Zhao, Mohamed Hussein, Thomas Norton, Anna J. Podolanczuk, Eleftherios Mylonakis, Gregory P. Geba	9
4	A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip 2024 ·SHILAP Revista de lepidopterología ·Stephen J. DiMartino, (unknown), Thomas J. Schnitzer, Haitao Gao, (unknown), (unknown), (unknown), K. C. Turner, Hazem E. Hassan, (unknown), John D. Davis, (unknown), (unknown), (unknown), Michael R. Fetell, (unknown), Gregory P. Geba, Paula Dakin	2
5	Association between allergic conditions and COVID-19 susceptibility and outcomes 2024 ·Annals of Allergy Asthma & Immunology ·Chao Chen, (unknown), (unknown), Andrea Fleisch Marcus, Mohamed Hussein, Jessica J. Jalbert, Gregory P. Geba	9
6	Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials 2023 ·Cancer Medicine ·Kusha Mohammadi, (unknown), Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek, Garen Manvelian, Robert Pordy, Sergio Fazio, Gregory P. Geba	3
7	Successful Clearance of 300 Day SARS-CoV-2 Infection in a Subject with B-Cell Depletion Associated Prolonged (B-DEAP) COVID by REGEN-COV Anti-Spike Monoclonal Antibody Cocktail 2021 ·Viruses ·Arnaud Drouin, (unknown), (unknown), (unknown), (unknown), Mark Zeller, Gregory P. Geba, (unknown), (unknown), (unknown), Di Tian, Matthew L. Boisen, Luis M. Branco, Kristian G. Andersen, James E. Robinson, Robert F. Garry, Dahlene N. Fusco	18
8	A Retrospective Study of COVID-19-Related Urgent Medical Visits and Hospitalizations After Outpatient COVID-19 Diagnosis in the US 2021 ·Advances in Therapy ·Wenhui Wei, Sumathi Sivapalasingam, Scott Mellis, Gregory P. Geba, Jessica J. Jalbert	6
9	Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial 2020 ·Annals of the Rheumatic Diseases ·Paula Dakin, Alan Kivitz, Joseph Gimbel, Nebojša Skrepnik, Stephen J. DiMartino, Chetachi A. Emeremni, Haitao Gao, Neil Stahl, David M. Weinreich, George D. Yancopoulos, Gregory P. Geba	26
10	A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma 2012 ·European Respiratory Journal ·Edward Piper, Christopher E. Brightling, Robert Niven, Chad K. Oh, Raffaella Faggioni, (unknown), Dewei She, Chris Kell, Richard May, Gregory P. Geba, Néstor A. Molfino	290
11	Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma 2011 ·European Respiratory Journal ·Edward Piper, Christopher E. Brightling, Robert Niven, Chad K. Oh, Raffaella Faggioni, (unknown), Dewei She, Chris Kell, Richard May, Gregory P. Geba, Néstor A. Molfino	7
12	Treatment of chronic autoimmune urticaria with omalizumab 2008 ·Journal of Allergy and Clinical Immunology ·Allen P. Kaplan, Kusumam Joseph, Robert Maykut, Gregory P. Geba, Robert K. Zeldin	200
13	OMALIZUMAB IMPROVES SYMPTOMS AND REDUCES RESCUE BETA-AGONIST USE IN OLDER PATIENTS WITH UNCONTROLLED ASTHMA 2005 ·CHEST Journal ·Robert Maykut, Marc Massanari, Farid Kianifard, Yamo Deniz, Colin Reisner, Robert K. Zeldin, Gregory P. Geba	1
14	The Analgesic Efficacy of Etoricoxib Compared with Oxycodone/Acetaminophen in an Acute Postoperative Pain Model: A Randomized, Double-Blind Clinical Trial 2004 ·Anesthesia & Analgesia ·David J. Chang, Paul J. Desjardins, Thomas King, Tara Erb, Gregory P. Geba	54
15	Assessment of in Vitro Delivered Dose of Formoterol via A New Multi-dose Dry Powder Inhaler: Reliable Delivery Over a Range of Clinically Relevant Inspiratory Flow Rates 2004 ·CHEST Journal ·Devendra Singh, Philippe T. Gilchrist, (unknown), (unknown), (unknown), Gregory P. Geba	1
16	Comparison of rofecoxib and a multidose oxycodone/acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial 2004 ·Current Medical Research and Opinion ·David J. Chang, Paul J. Desjardins, Steven Bird, Peter M. Black, Erluo Chen, Richard A. Petruschke, Gregory P. Geba	25
17	Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial 2004 ·Arthritis & Rheumatism ·Bernard R. Rubin, (unknown), Sandra Navarra, (unknown), John Londoño, (unknown), (unknown), Erluo Chen, (unknown), Richard A. Petruschke, Zafer E. Ozturk, Gregory P. Geba	131
18	Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: A randomized, placebo-controlled clinical trial 2002 ·Clinical Therapeutics ·David J. Chang, Paul J. Desjardins, Erluo Chen, Adam B. Polis, (unknown), (unknown), Gregory P. Geba	65
19	Topical tacrolimus and cyclosporin A differentially inhibit early and late effector phases of cutaneous delayed‐type and immunoglobulin E hypersensitivity 2001 ·Immunology ·Gregory P. Geba, Włodzimierz Ptak, (unknown)	16
20	Serotonin Initiation of Delayed-Type Hypersensitivity: Mediation by a Primitive Thy-1<sup>+</sup> Antigen-Specific Clone or by Specific Monoclonal IgE Antibody 1991 ·Skin Pharmacology and Physiology ·Philip W. Askenase, (unknown), Isabelle Millet, Vipin Paliwal, Rajani Ramabhadran, Carolyn L. Rochester, Gregory P. Geba, Włodzimierz Ptak	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact